Polycystic Ovary Syndrome Renamed to SOMP to Prioritize Metabolic Health

The World Health Organization (WHO), in coordination with a consensus of 56 organizations, has announced that Polycystic Ovary Syndrome (PCOS) will be renamed to Metabolic Polyendocrine Ovary Syndrome (SOMP). This shift in terminology is designed to pivot the medical focus toward a more comprehensive metabolic diagnosis, ensuring that millions of women can receive more accurate and effective care.

The decision to transition to the name SOMP stems from a need to move beyond a narrow focus on the ovaries and instead prioritize the systemic endocrine and metabolic issues associated with the condition. By broadening the diagnostic lens, health experts aim to better identify and treat patients who may present with symptoms such as unexplained fatigue and acne, which are often linked to the disorder.

To allow the medical community and healthcare providers to adapt, a three-year transition period has been established for the implementation of the new name. This gradual rollout is intended to integrate the updated nomenclature into clinical practice while emphasizing a more holistic approach to patient health.

This update underscores the evolving understanding of endocrine disorders and the importance of comprehensive screening. By renaming the syndrome to reflect its metabolic and polyendocrine nature, the medical community seeks to eliminate diagnostic gaps and improve the overall quality of life for those affected by the condition.